Replimune Securities Class Action Lawsuit Alert: Key Deadlines and Details

Strategic Insights -

Purchasers of Replimune Group, Inc. securities between November 22, 2024, and July 21, 2025, may be entitled to compensation in a securities class action lawsuit. The lawsuit claims that Replimune's statements about its business, operations, and prospects were materially false and misleading during this period. A class action has been filed, and the court requires a lead plaintiff to be appointed by September 22, 2025.

Key Takeaways:

  • The lawsuit alleges that Replimune's statements about the IGNYTE trial were misleading, and the FDA deemed the trial inadequate and not well-controlled.
  • The lawsuit claims that investors suffered damages after the true details of Replimune's business and operations entered the market.
  • The deadline to join the Replimune class action is September 22, 2025, and interested parties can contact Phillip Kim, Esq., at 866-767-3653 or case@rosenlegal.com for more information.
  • The Rosen Law Firm, representing investors globally, is seeking lead plaintiff status to direct the litigation.
  • The firm has a track record of success in securing hundreds of millions of dollars for investors and has been ranked as the top securities class action settlement firm in 2017.

Statistics:

  • The class period spans from November 22, 2024, to July 21, 2025.
  • The lawsuit claims that investors suffered damages after the true details of Replimune's business and operations entered the market.
  • The Rosen Law Firm has secured over $438 million for investors in 2019 alone.
  • The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors.

Sources:

  • Newsfile Corp.

Note: All information in this summary is based directly on the provided press release and does not include any additional details or dates not explicitly stated in the source material.